Summary by Moomoo AI
Clearmind Medicine Inc., a clinical-stage biotech company, has issued a letter to shareholders on April 9, 2024, outlining significant progress in its research and development efforts, particularly with its flagship compound CMND-100. The CEO, Dr. Adi Zuloff-Shani, highlighted the company's advancements in treating alcohol use disorder (AUD) and other mental health conditions. Clearmind has received approval from the Israeli Ministry of Health for a Phase I/IIa clinical trial for CMND-100, which has shown promising results in pre-clinical studies without inducing hallucinations. The company has completed a Type A meeting with the FDA, formed a Data and Safety Monitoring Board, secured IRB Approval in Israel, and announced U.S. clinical trial sites at Johns Hopkins University and Yale...Show More